90 related articles for article (PubMed ID: 11051596)
21. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
[TBL] [Abstract][Full Text] [Related]
22. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
23. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype.
Fried MW; Shiffman M; Sterling RK; Weinstein J; Crippin J; Garcia G; Wright TL; Conjeevaram H; Reddy KR; Peter J; Cotsonis GA; Nolte FS
Am J Gastroenterol; 2000 Nov; 95(11):3225-9. PubMed ID: 11095346
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.
Sherman KE; Sjogren M; Creager RL; Damiano MA; Freeman S; Lewey S; Davis D; Root S; Weber FL; Ishak KG; Goodman ZD
Hepatology; 1998 Apr; 27(4):1128-35. PubMed ID: 9537454
[TBL] [Abstract][Full Text] [Related]
25. Polaprezinc (Zinc-L-Carnosine Complex) as an Add-on Therapy for Binge Eating Disorder and Bulimia Nervosa, and the Possible Involvement of Zinc Deficiency in These Conditions: A Pilot Study.
Sakae K; Suka M; Yanagisawa H
J Clin Psychopharmacol; 2020; 40(6):599-606. PubMed ID: 33044355
[TBL] [Abstract][Full Text] [Related]
26. The possible role of zinc and metallothionein in the liver on the therapeutic effect of IFN-alpha to hepatitis C patients.
Nagamine T; Takagi H; Hashimoto Y; Takayama H; Shimoda R; Nomura N; Suzuki K; Mori M; Nakajima K
Biol Trace Elem Res; 1997; 58(1-2):65-76. PubMed ID: 9363321
[TBL] [Abstract][Full Text] [Related]
27. Induction of type 1 interferon receptor by zinc in U937 cells.
Nagamine T; Nakajima K; Takada H; Sekine Y; Suzuki K
Cytokine; 2009 Jun; 46(3):346-50. PubMed ID: 19362011
[TBL] [Abstract][Full Text] [Related]
28. Residence time of polaprezinc (zinc L-carnosine complex) in the rat stomach and adhesiveness to ulcerous sites.
Furuta S; Toyama S; Miwa M; Itabashi T; Sano H; Yoneta T
Jpn J Pharmacol; 1995 Apr; 67(4):271-8. PubMed ID: 7650862
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Polaprezinc (Zinc Compound) on Zinc Deficiency: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials Using Individual Patient Data.
Furihata K; Tsuchikawa M; Miwa T; Naito Y; Oba K; Sakagami M
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32316581
[TBL] [Abstract][Full Text] [Related]
30. Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer.
Watanabe T; Ishihara M; Matsuura K; Mizuta K; Itoh Y
Int J Cancer; 2010 Oct; 127(8):1984-90. PubMed ID: 20104529
[TBL] [Abstract][Full Text] [Related]
31. Polaprezinc, a zinc compound, is distributed to the lingual epithelium and increases its zinc concentration in zinc-deficient rats.
Hamano H; Yoshinaga K; Tanaka T; Eta R; Horii T; Kawabata Y; Furuta S; Takei M
Life Sci; 2009 Nov; 85(21-22):759-64. PubMed ID: 19846043
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effect of polaprezinc on the inflammatory response to Helicobacter pylori.
Handa O; Yoshida N; Tanaka Y; Ueda M; Ishikawa T; Takagi T; Matsumoto N; Naito Y; Yoshikawa T
Can J Gastroenterol; 2002 Nov; 16(11):785-9. PubMed ID: 12464972
[TBL] [Abstract][Full Text] [Related]
33. A zinc-containing compound, Polaprezinc, is effective for patients with taste disorders: randomized, double-blind, placebo-controlled, multi-center study.
Sakagami M; Ikeda M; Tomita H; Ikui A; Aiba T; Takeda N; Inokuchi A; Kurono Y; Nakashima M; Shibasaki Y; Yotsuya O
Acta Otolaryngol; 2009 Oct; 129(10):1115-20. PubMed ID: 19037756
[TBL] [Abstract][Full Text] [Related]
34. Effects of polaprezinc on morphological change of the tongue in zinc-deficient rats.
Kinomoto T; Sawada M; Ohnishi Y; Yamaguchi T; Tsuge S; Ogawa S; Washizuka M; Minaguchi J; Mera Y; Takehana K
J Oral Pathol Med; 2010 Sep; 39(8):617-23. PubMed ID: 21054547
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy and safety of polaprezinc as a preventive drug for radiation-induced stomatitis].
Masayuki F; Norihiko K; Keita T; Miwa I; Masayuki I; Toshihiko I; Hiromi F; Chikaaki M; Norio N
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 Mar; 62(4):144-50. PubMed ID: 12043217
[TBL] [Abstract][Full Text] [Related]
36. Beneficial effect of polaprezinc on cardiac function post-myocardial infarction: A prospective and randomized clinical trial.
Yoshikawa F; Nakajima T; Hanada M; Hirata K; Masuyama T; Aikawa R
Medicine (Baltimore); 2019 Mar; 98(10):e14637. PubMed ID: 30855449
[TBL] [Abstract][Full Text] [Related]
37. Utility of polaprezinc in reducing toxicities during radiotherapy: a literature review.
Doi H; Kuribayashi K; Kijima T
Future Oncol; 2018 Aug; 14(19):1977-1988. PubMed ID: 30074413
[TBL] [Abstract][Full Text] [Related]
38. Effect of polaprezinc on taste disorders in zinc-deficient rats.
Hamano H; Yoshinaga K; Eta R; Emori Y; Kawasaki D; Iino Y; Sawada M; Kuroda H; Takei M
Biofactors; 2006; 28(3-4):185-93. PubMed ID: 17473379
[TBL] [Abstract][Full Text] [Related]
39. Improvement of Dysgeusia by Polaprezinc, a Zinc-L-carnosine, in Outpatients Receiving Cancer Chemotherapy.
Fujii H; Hirose C; Ishihara M; Iihara H; Imai H; Tanaka Y; Matsuhashi N; Takahashi T; Yamaguchi K; Yoshida K; Suzuki A
Anticancer Res; 2018 Nov; 38(11):6367-6373. PubMed ID: 30396959
[TBL] [Abstract][Full Text] [Related]
40. [The effects of Rebamipide and Polaprezinc mouthwash and uptake on mucositis induced by chemotherapy].
Fukuhara K; Terakura M; Katsuragi K; Kodama S; Morisya Y; Hayaishi Y; Nakanishi C
Gan To Kagaku Ryoho; 2011 Dec; 38(13):2603-6. PubMed ID: 22189226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
